deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT03220178

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (PRECYCLE)

PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of eHealth-based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib and an Aromatase Inhibitor- or Palbociclib and Fulvestrant

Sponsor: AGO-B

Conditions Breast Neoplasm
Interventions Anastrozole Exemestane Fulvestrant Letrozole Palbociclib
Updated 14 times since 2017 Last updated: Dec 16, 2021 Started: Jul 24, 2017 Primary completion: Dec 7, 2021 Completion: Dec 7, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to COVID-19 pandemic, study cannot be finished in planned timeframe.

Other Breast Neoplasm trials with similar outcome

Browse all Breast Neoplasm trials

Listed as NCT03220178, this PHASE4 trial focuses on Breast Neoplasm and remains terminated or withdrawn. Sponsored by AGO-B, it has been updated 14 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2017 – ~Mar 2018 · 7 months · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~May 2020 · 13 months · monthly snapshot~May 2020 – ~Dec 2020 · 7 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Nov 2022 · 9 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 21 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  3. Nov 2022 — Jul 2024 [monthly]

    Terminated PHASE4

  4. Feb 2022 — Nov 2022 [monthly]

    Terminated PHASE4

    Status: Active Not Recruiting → Terminated

  5. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

▶ Show 9 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE4

  2. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

  3. May 2020 — Dec 2020 [monthly]

    Recruiting PHASE4

  4. Apr 2019 — May 2020 [monthly]

    Recruiting PHASE4

  5. Nov 2018 — Apr 2019 [monthly]

    Recruiting PHASE4

  6. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE4

  7. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE4

  8. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  9. Aug 2017 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AGO-B
  • AGO-TraFo
  • Cankado GmbH
  • Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.
  • Palleos Healthcare GmbH
  • Pfizer
  • WSG WOMEN´S HEALTHCARE STUDY GROUP
Data source: Palleos Healthcare GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations